DUROLANE

Contact us

Bioventus Coöperatief U.A.
Taurusavenue 31
2132 LS Hoofddorp
The Netherlands
Tel toll free 0800 05 16 384 (UK)
Tel toll free 1800 552 197 (Ireland)

Email us

  • Title
  •  
  • Where did you hear about DUROLANE?
  •  
  •  
  • Your message
  • We may use the data you submit to respond to your query, for the administration of our contacts, to improve this site or marketing related purposes and will be processed in accordance with the Data Protection Act 1998. We may, from time to time, send you information which we believe may be of interest to you, such as details of our products and services. If you do not wish us to do so then please
  • your sensitive personal data (such as health data) for these purposes. You also consent to our transferring your information to countries outside of Europe if necessary for such purposes. If we do make such a transfer we will, if appropriate, put a contract in place to ensure that your information is protected. We do not sell your information. For more information, view our Terms of Use and Privacy Policy. If you have further questions about our Privacy Policy, please contact us using the form above, or via any of the methods described on our contact page.
  •  

Bioventus

Summary of Indications for Use
DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.
You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling (1mL / 3mL).

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2017 Bioventus LLC.

Durolane-since-2001
*First introduced in the European Union in 2001.

To learn more about DUROLANE or for contact information, please select your location to continue.

Osteoarthritis: The Ongoing Challenges to Manage Pain

https://player.vimeo.com/video/125047428

Osteoarthritis: The Ongoing Challenges to Manage Pain